{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:09:49Z","timestamp":1790633389779,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T00:00:00Z","timestamp":1556236800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005646","name":"Actelion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008089","name":"Fondazione Internazionale Menarini","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008089","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007560","name":"Chiesi Farmaceutici","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.chest.2019.04.015","type":"journal-article","created":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T19:54:47Z","timestamp":1556567687000},"page":"706-714","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Association of Angiotensin Modulators With the Course of Idiopathic Pulmonary Fibrosis"],"prefix":"10.1016","volume":"156","author":[{"given":"Michael","family":"Kreuter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Lederer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Molina-Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imre","family":"Noth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Valenzuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Frankenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Weycker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Atwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus-Uwe","family":"Kirchgaessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Cottin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.chest.2019.04.015_bib1","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.chest.2019.04.015_bib2","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","article-title":"Clinical course and prediction of survival in idiopathic pulmonary fibrosis","volume":"183","author":"Ley","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.chest.2019.04.015_bib3","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1164\/rccm.200602-163OC","article-title":"Incidence and prevalence of idiopathic pulmonary fibrosis","volume":"174","author":"Raghu","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.chest.2019.04.015_bib4","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1183\/09031936.00217614","article-title":"Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry","volume":"46","author":"Behr","year":"2015","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.chest.2019.04.015_bib5","doi-asserted-by":"crossref","first-page":"e0151425","DOI":"10.1371\/journal.pone.0151425","article-title":"Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis","volume":"11","author":"Kreuter","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.chest.2019.04.015_bib6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12931-017-0621-y","article-title":"Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: INSIGHTS-IPF registry","volume":"18","author":"Kreuter","year":"2017","journal-title":"Respir Res"},{"issue":"7","key":"10.1016\/j.chest.2019.04.015_bib7","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.rmed.2010.02.008","article-title":"Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis","volume":"104","author":"Nathan","year":"2010","journal-title":"Respir Med"},{"key":"10.1016\/j.chest.2019.04.015_bib8","first-page":"A4980","article-title":"Cardiovascular events in phase 3 trials of pirfenidone in idiopathic pulmonary fibrosis (IPF) [abstract]","volume":"193","author":"Glassberg","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.chest.2019.04.015_bib9","first-page":"CD009096","article-title":"Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension","volume":"8","author":"Li","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.chest.2019.04.015_bib10","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1161\/01.RES.0000105920.33926.60","article-title":"Cellular mechanism of vasoconstriction induced by angiotensin II: it remains to be determined","volume":"93","author":"Kanaide","year":"2003","journal-title":"Circ Res"},{"issue":"1","key":"10.1016\/j.chest.2019.04.015_bib11","doi-asserted-by":"crossref","first-page":"L178","DOI":"10.1152\/ajplung.00009.2008","article-title":"Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis","volume":"295","author":"Li","year":"2008","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"2","key":"10.1016\/j.chest.2019.04.015_bib12","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.resinv.2012.12.005","article-title":"Preventive effect of irbesartan on bleomycin-induced lung injury in mice","volume":"51","author":"Tanaka","year":"2013","journal-title":"Respir Investig"},{"issue":"2","key":"10.1016\/j.chest.2019.04.015_bib13","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1159\/000430131","article-title":"Angiotensin-converting enzyme 2 attenuates bleomycin-induced lung fibrosis in mice","volume":"36","author":"Wang","year":"2015","journal-title":"Cell Physiol Biochem"},{"issue":"5","key":"10.1016\/j.chest.2019.04.015_bib14","doi-asserted-by":"crossref","first-page":"L887","DOI":"10.1152\/ajplung.00432.2005","article-title":"Extravascular sources of lung angiotensin peptide synthesis in idiopathic pulmonary fibrosis","volume":"291","author":"Li","year":"2006","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"4","key":"10.1016\/j.chest.2019.04.015_bib15","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1183\/09031936.00015808","article-title":"Angiotensinogen gene G-6A polymorphism influences idiopathic pulmonary fibrosis disease progression","volume":"32","author":"Molina-Molina","year":"2008","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.chest.2019.04.015_bib16","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1136\/thx.2005.051946","article-title":"Losartan attenuates bleomycin induced lung fibrosis by increasing prostaglandin E2 synthesis","volume":"61","author":"Molina-Molina","year":"2006","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.chest.2019.04.015_bib17","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.biocel.2011.11.019","article-title":"Angiotensin signalling in pulmonary fibrosis","volume":"44","author":"Uhal","year":"2012","journal-title":"Int J Biochem Cell Biol"},{"issue":"12","key":"10.1016\/j.chest.2019.04.015_bib18","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.2174\/138161207780618885","article-title":"Angiotensin-TGF-\u03b21 crosstalk in human idiopathic pulmonary fibrosis: autocrine mechanisms in myofibroblasts and macrophages","volume":"13","author":"Uhal","year":"2007","journal-title":"Curr Pharm Des"},{"issue":"12","key":"10.1016\/j.chest.2019.04.015_bib19","doi-asserted-by":"crossref","first-page":"24029","DOI":"10.3390\/ijms141224029","article-title":"Hypoxia-induced collagen synthesis of human lung fibroblasts by activating the angiotensin system","volume":"14","author":"Liu","year":"2013","journal-title":"Int J Mol Sci"},{"issue":"13","key":"10.1016\/j.chest.2019.04.015_bib20","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.2174\/138161207780618777","article-title":"Effect of an angiotensin II receptor blocker and two angiotensin converting enzyme inhibitors on transforming growth factor-\u03b2 (TGF-\u03b2) and \u03b1-actomyosin (\u03b1 SMA), important mediators of radiation-induced pneumopathy and lung fibrosis","volume":"13","author":"Molteni","year":"2007","journal-title":"Curr Pharm Des"},{"issue":"22","key":"10.1016\/j.chest.2019.04.015_bib21","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A\u00a0phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"9779","key":"10.1016\/j.chest.2019.04.015_bib22","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.chest.2019.04.015_bib23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S2213-2600(16)30326-5","article-title":"Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis","volume":"5","author":"Nathan","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.chest.2019.04.015_bib24","first-page":"A4979","article-title":"Cardiovascular risk factors, comorbidities and concomitant medications from three phase 3 trials of pirfenidone in idiopathic pulmonary fibrosis [abstract]","volume":"193","author":"Glassberg","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"9685","key":"10.1016\/j.chest.2019.04.015_bib25","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(09)60551-1","article-title":"Effect of Interferon Gamma-1b on Survival in Patients with Idiopathic Pulmonary Fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial","volume":"374","author":"King","year":"2009","journal-title":"Lancet"},{"issue":"398","key":"10.1016\/j.chest.2019.04.015_bib26","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/01621459.1987.10478441","article-title":"Model-based direct adjustment","volume":"82","author":"Rosenbaum","year":"1987","journal-title":"J\u00a0Am Stat Assoc"},{"issue":"3","key":"10.1016\/j.chest.2019.04.015_bib27","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"issue":"21","key":"10.1016\/j.chest.2019.04.015_bib28","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1042\/CS20160193","article-title":"Angiotensin-(1-7) decreases the expression of collagen I via TGF-\u03b21\/Smad2\/3 and subsequently inhibits fibroblast-myofibroblast transition","volume":"130","author":"Zhou","year":"2016","journal-title":"Clin Sci"},{"key":"10.1016\/j.chest.2019.04.015_bib29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coph.2017.12.002","article-title":"Targeting the renin-angiotensin system as novel therapeutic strategy for pulmonary diseases","volume":"40","author":"Tan","year":"2017","journal-title":"Curr Opin Pharmacol"},{"issue":"2","key":"10.1016\/j.chest.2019.04.015_bib30","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S0008-6363(00)00044-4","article-title":"Angiotensin II, adhesion, and cardiac fibrosis","volume":"46","author":"Schnee","year":"2000","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.chest.2019.04.015_bib31","doi-asserted-by":"crossref","first-page":"40523","DOI":"10.1038\/srep40523","article-title":"Pirfenidone controls the feedback loop of the AT1R\/p38 MAPK\/renin-angiotensin system axis by regulating liver X receptor-\u03b1 in myocardial infarction-induced cardiac fibrosis","volume":"7","author":"Li","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.chest.2019.04.015_bib32","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/hr.2011.139","article-title":"The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice","volume":"35","author":"Yamazaki","year":"2012","journal-title":"Hypertens Res"},{"issue":"4","key":"10.1016\/j.chest.2019.04.015_bib33","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/resp.12781","article-title":"Cardiovascular and antacid treatment and mortality in oxygen-dependent pulmonary fibrosis: a population-based longitudinal study","volume":"21","author":"Ekstrom","year":"2016","journal-title":"Respirology"},{"key":"10.1016\/j.chest.2019.04.015_bib34","first-page":"59","article-title":"The renin-angiotensin-aldosterone-system and right heart failure in congenital heart disease","volume":"11","author":"Andersen","year":"2016","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"5","key":"10.1016\/j.chest.2019.04.015_bib35","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00408-012-9410-z","article-title":"Treatment of idiopathic pulmonary fibrosis with losartan: a pilot project","volume":"190","author":"Couluris","year":"2012","journal-title":"Lung"},{"key":"10.1016\/j.chest.2019.04.015_bib36","article-title":"Angiotensin II receptor agonist for treating pulmonary fibrosis","author":"Dahl\u00f6f","year":"2016","journal-title":"Patent application WO-2016139475-A1"},{"issue":"5","key":"10.1016\/j.chest.2019.04.015_bib37","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S2213-2600(16)00067-9","article-title":"Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis","volume":"4","author":"Kreuter","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.chest.2019.04.015_bib38","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1136\/thoraxjnl-2016-208819","article-title":"Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis","volume":"72","author":"Kreuter","year":"2017","journal-title":"Thorax"},{"key":"10.1016\/j.chest.2019.04.015_bib39","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1183\/13993003.01482-2016","article-title":"Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis: methodological concerns","volume":"48","author":"Kreuter","year":"2016","journal-title":"Eur Respir J"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369219308827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369219308827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T22:58:09Z","timestamp":1762124289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369219308827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0012369219308827"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2019.04.015","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of Angiotensin Modulators With the Course of Idiopathic Pulmonary Fibrosis","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2019.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc under license from the American College of Chest Physicians.","name":"copyright","label":"Copyright"}]}}